Science of Early Detection
Within the Science of Early Detection and Intervention Focus Area, RTFCCR intends to support interventional clinical trials, as well as clinical validation studies aimed at the detection of and intervention in early cancer or pre-cancerous changes to try to slow or prevent cancer development and lethality.
- The study may improve existing or develop new tests/ test methods/ technologies/ devices.
- The study should be aimed at populations at high risk of development or recurrence or of progression of pre-cancer to cancer.
- Studies with a clinical intervention and a clinical endpoint will be prioritized.
RTFCCR does not support the early development of a diagnostic tool without analytical validation in cancer populations or samples. Larger scale clinical validation of such tools already having analytical validation is in scope. RTFCCR does not support population screening. Companion diagnostics studies are not within RTFCCR focus.
Applicants can contact us at email@example.com to clarify any questions or doubts.
- Use of blood testing for detection of disease occurrence or recurrence.
- Use of AI to improve imaging and detection tools to distinguish benign lesions from malignant formations.
- Development or improvement of a test to better stratify the population into levels of cancer risk to inform early detection.
Stages of the cancer journey
- A tumor originates within normal tissues, when one or more cells experience aberrant genetic events and start proliferating in an uncontrolled manner
- This change in cell behavior is caused by a genetic event (a mutation). The cause of the cancer-causing mutation can be sporadic or due to environmental factors (carcinogens, UV etc)
- These abnormally growing cells (dysplasia) can develop into a mass (in situ) that can start interacting with the surrounding cells (tissue microenvironment).
- The in situ tumor and can further develop, becoming an invasive tumor. Through cell signaling, the tumor stimulates capillary growth, to have access to nutrients in the blood. Moreover, it also convinces the body immune system (lymphocytes and macrophages) to support its growth instead of fighting it.
- When the change in cell behavior reaches a certain stage, it can be detected, and interventions can be employed to eradicate it.
- In some cases, the intervention (e.g., neo-adjuvant, chemotherapy, radiotherapy, surgery, adjuvant treatments) does not eradicate the tumor completely: some cells can be left behind and, with time, begin proliferating again, resulting in tumor recurrence /relapse.
- Sometimes before, during or after treatment, the tumor can shed living cells in blood or lymphatic vessels, which can move to colonize other tissues (metastasis)
The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) seeks to support clinical cancer research across different stages of the cancer journey, with specific focus on the following strategic focus areas:
- Science of Early Detection and Intervention, where support is provided for studies aimed at detecting abnormal cells at the earliest time possible and intervening to eliminate them before they can develop into more aggressive tumor stages.
- Improved Patient Outcomes, where support is provided for interventional clinical trials that advance therapeutic approaches with the best possible outcomes and the least toxicity
We accept Letters of Intent (LOIs) all year round with cutoff deadlines for internal assessment three times per year. Once you have submitted your LOI, you will receive further information regarding timing and next steps.
Pre-application grants provide gap funding to support patient experts’ helping to develop grant applications/ protocols.
Request for Proposal
At the moment there are no other open funding opportunities.